|
, J1 n. Y; m, a& J8 d, e' v3 S
Vaccines, 6th Edition $ \( ~7 v) |# d T: ?1 ]( X
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.
/ f$ a, t" x5 i) ^9 I7 O( }/ |! C4 I4 a# L p9 E
http://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606" |2 b: Q! V0 l3 I- O7 Z
3 r9 y1 V/ N/ L% \& ~+ A- h( xSECTION 1: General aspects of vaccination
$ g$ B: n; @: A5 K1 l4 l7 w8 c1 A short history of vaccination 18 i8 |: V+ }$ T) c# _; Z% r# y5 I
2 Vaccine immunology 146 D5 e- ]- `1 Y2 Z/ _9 a# `
3 The vaccine industry 33, v! L* N7 m8 \% ~' ^# _6 X
4 Vaccine manufacturing 449 ]" t$ x3 J; d& O8 N4 v
5 Evolution of adjuvants across the centuries 58
" G/ _( ^) Z R, o0 }/ l0 _' B6 Vaccine additives and manufacturing residuals in the United States:
. t3 ?: e2 P; X* plicensed vaccines 71$ Z6 F) G; c+ M% j7 o
7 Passive immunization 80$ Y7 m7 X5 V0 B4 T
8 General immunization practices 88
Q! ?7 X1 B9 p+ y9 F6 GSECTION 2: Licensed vaccines- l& X$ D: U1 m+ g
9 Adenovirus vaccines 113
% P% F* p) `( ^1 d O+ ^10 Anthrax vaccines 127: a: i# m+ a+ Z4 i1 @% ^' D7 t i& ?
11 Cholera vaccines 141
% l9 W9 H8 H6 G w, H" c% O, R12 Diphtheria toxoid 153
! e* G; E+ x8 n13 Haemophilus influenzae vaccines 167
# y1 N' E, r* H( B14 Hepatitis A vaccines 1835 K! {; P! m( K+ L
15 Hepatitis B vaccines 205
$ {- m$ B6 W. |' U- Z4 w2 _16 Human papillomavirus vaccines 235
" s7 }6 K; R, K/ Z4 o9 u4 |17 Inactivated influenza vaccines 257
/ \3 z. u6 {; ?& x; A, @3 P& p O18 Influenza vaccine-live 294
$ W0 F8 `2 a0 C9 ]3 `. Z p& m19 Japanese encephalitis vaccines 312& s0 R3 u- n8 e4 ?
20 Measles vaccines 352; G1 N/ s/ f# @! ~9 C, y( o8 T
21 Meningococcal vaccines 3887 P& z. y3 I) @' g- s" v) _9 I
22 Mumps vaccine 419
2 j! S; t, [& u$ c23 Pertussis vaccines . 447, P0 ^3 M% d4 B
24 Plague vaccines 493
- G% V0 b# q1 K5 f7 p* ^25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504. g1 Y2 ~1 P8 y
26 Pneumococcal polysaccharide vaccines 542# x9 W7 O6 g% C) Y6 F
27 Poliovirus vaccine-inactivated . 5739 M( _# S- U; |5 r/ n. R3 h
28 Poliovirus vaccine-live 598
: T5 \/ ]5 I3 V+ [, |# _& t29 Rabies vaccines .646
. s' L- s9 e C( ^! @30 Rotavirus vaccines . 669
# d( h) d, \* l( J31 Rubella vaccine 688
1 @! ]( \( }9 Y; f5 g32 Smallpox and vaccinia 7187 ]2 m% k8 A% g6 t7 S5 f& B) m
33 Tetanus toxoid 7460 b- F7 H, R! E( e" E, U ~
34 Tick-borne encephalitis virus vaccines 773
! K3 S6 P0 ^- m# `) F$ s35 Tuberculosis vaccines 789
0 O3 m9 i# ]2 J, i36 Typhoid fever vaccines 8125 q% o9 @: c" ?. A
37 Varicella vaccine 8377 |4 _ \0 I$ J' B" E
38 Yellow fever vaccine 870, h# _4 w1 x: Y) L; V4 y: z+ c
39 Zoster vaccine 969
d3 |; ~& H: [7 c2 n, S& ?0 _- }2 f40 Combination vaccines 981
7 E5 T' |; v% wSECTION 3: Vaccines in development and new vaccine strategies9 J# \% i- o6 F( k& r
41 Biodefense and special pathogen vaccines 10086 T8 w4 s% h) [, Z5 A8 ]9 m, P
42 Therapeutic cancer vaccines 1018
u0 T9 B ?1 c: X43 Cytomegalovirus vaccines 1032
+ R6 Z# ?1 a0 |& K/ A! r# k( f44 Dengue vaccines 10420 p$ U1 g$ ~; J O& O5 I- S4 l
45 Diarrhea caused by bacteria 1052
0 V7 W6 x- m% Q46 Ebola vaccine 1060
7 V& B5 f' i8 x/ s' T0 U47 Epstein-Barr virus vaccines 1068" \+ z5 V4 Y# `$ ]: b$ t7 ^
48 Hepatitis C vaccines 10748 B/ v0 [1 c r9 Y7 c
49 Hepatitis E vaccines 1085& h3 v/ h/ u0 g9 {) y b
50 Herpes simplex virus vaccines 1090( l( A! O1 j4 s# m! E7 @" H8 `0 Q
51 Human immunodeficiency virus vaccines 10977 i7 d0 I! _* F2 v( t
52 Lyme disease vaccines 1122 y0 b1 R$ ?0 X8 `
53 Malaria vaccines 1133! n( t, O, a, \% G9 g$ x" s
54 Noninfectious disease vaccines 11380 s1 i c) B; y" Y7 y i
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146' @% H' o- d, ?2 r/ c$ A# K2 [
56 Parasitic disease vaccines 1154
3 }7 c# B. r5 O. W: w% P6 u57 Staphylococcus aureus vaccines 1161
+ [5 G) Q8 s4 c5 `58 Streptococcus group A vaccines 1169& a9 z6 {% z' U# T7 g! \* g
59 Streptococcus group B vaccines 1176
8 H( Z) _. t, k* ^2 G$ V% S' h60 Technologies for making new vaccines 1182) L7 M5 |/ b; u6 `, P
61 Alternative vaccine delivery methods 1200: b- o9 G( Z% B- ?( P+ R% Z
62 The development of gene-based vectors for immunization 1232
9 E: d9 [4 O8 r1 c, ^! XSECTION 4: Vaccination of special groups
5 v$ D z0 {/ G63 Vaccination of immunocompromised hosts 1243
* I: @0 g H# b4 [8 s64 Vaccination of human immunodeficiency virus-infected persons 1257
4 C) j$ T- i) z' N65 Vaccines for international travel 1270
3 s1 c p2 Z. z66 Vaccines for health care personnel 1290* @, n( I5 V! H/ Y+ p9 V; ~, A
SECTION 5: Public health and regulatory issues
8 W, z0 `/ Z7 y% T9 V; P! ?67 Immunization in the United States 1310
- B. L5 w1 Y+ E4 ?68 Immunization in Europe . 1334$ ^, u0 C# Q6 p* Q: _$ g, h
69 Immunization in the Asia-Pacific region 13539 d/ C1 ~8 o6 r8 m
70 Immunization in developing countries 1369 B6 S/ [9 D" R+ j/ R
71 Community immunity 1395 I) @0 C+ `2 |! R$ C6 j
72 Economic analyses of vaccine policies 1413, Y5 L- @3 Y5 M! g2 F2 h
73 Regulation and testing of vaccines 1427
9 a& e [& H- i1 B9 _1 S; @74 Regulation of vaccines in Europe 1447; j0 x9 G& s! h& A! ?2 F7 ~
75 Regulation of vaccines in developing countries 1454
( ?- x/ t ~# ]4 C# d: t1 ]1 |* c76 Vaccine safety 1464' E5 m% c( I1 z1 [
77 Legal issues . 1481- ?( n8 |- I) z6 j1 ?) {
78 Ethics 1508
) F/ k3 q- u1 D$ T) O8 z
9 d9 {* ^7 S; J" s6 G8 V* m3 C1 @- u: n$ ^* M6 D3 b
5 k! G& B+ d" q+ E2 \9 ^" P' q0 O% t" O/ q [
|
|